Stephan Christgau

Partner, Seed Investments at Novo Holding A/S

Stephan Christgau

Stephan Christgau

Partner, Seed Investments at Novo Holding A/S

Overview
Career Highlights

Osteologix, Inc. (Inactive)
Osteologix Holdings Plc

RelSci Relationships

489

Number of Boards

16

Birthday

1965

Age

53

Relationships
RelSci Relationships are individuals Stephan Christgau likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Insusense ApS

Relationship likelihood: Strong

Partner, Life Sciences at IP Group Plc

Relationship likelihood: Strong

Partner at Novo Ventures

Relationship likelihood: Strong

General Partner at SEED Capital Management I/S

Relationship likelihood: Strong

Chief Executive Officer & Director at Adenium Biotech ApS

Relationship likelihood: Strong

Chief Executive Officer at Forendo Pharma Oy

Relationship likelihood: Strong

Managing Partner Seed Investments at Novo Holding A/S

Relationship likelihood: Strong

Co-Founder at Galecto Biotech ApS

Relationship likelihood: Strong

Principal at Novo Seeds

Relationship likelihood: Strong

Principal, Seed Investments at Novo Holding A/S

Relationship likelihood: Strong

Paths to Stephan Christgau
Potential Connections via
Relationship Science
You
Stephan Christgau
Partner, Seed Investments at Novo Holding A/S
Education
PhD

For almost two centuries DTU, Technical University of Denmark, has been dedicated to fulfilling the vision of H.C. Ørsted – the father of electromagnetism – who founded the university in 1829 to develop and create value using the natural sciences and the technical sciences to benefit society. Today, DTU is ranked as one of the foremost technical universities in Europe, continues to set new records in the number of publications, and persistently increase and develop our partnerships with industry, and assignments accomplished by DTU’s public sector consultancy.

Career History
Senior Partner
2007 - Current

Novo Seeds is an active manager which provides funding for seed and early-stage capital requirements, as well as providing management support. The firm invests in startups from Northern Europe operating in the health technology and health services sector, and industries such as biotechnology and medical specialties.

Investment Director
2007 - Current

Novo Ventures is an active manager which provides funding for early and later-stage capital requirements, and provides management support. The firm invests in both public and private companies from Northern Europe and the United States. Novo Ventures targets companies operating in the health technology and health services sector, and industries such as biotechnology and medical specialties. It looks to take minority stake positions in its investments, as well as a seat on the board.

Partner, Seed Investments
Current

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation's assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Boards & Committees
Member, Board of Directors
Current

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Chairman
Current
Director
Current

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane Sørensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Member, Committee on Exploratory Pre-Seed Grants
Prior - 2015

Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stephan Christgau. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stephan Christgau's profile does not indicate a business or promotional relationship of any kind between RelSci and Stephan Christgau.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/stephan-christgau-3202578
  • https://relationshipscience.com/person/stephan-christgau-3202578